A 48-Week, Open Label, Study to Evaluate the Efficacy and Safety of AMONDYS 45, EXONDYS 51, VYONDYS 53 in Subjects With DuchenneMuscular Dystrophy Carrying Eligible DMD Duplications
Latest Information Update: 28 Oct 2023
At a glance
- Drugs Casimersen (Primary) ; Eteplirsen (Primary) ; Golodirsen (Primary)
- Indications Duchenne muscular dystrophy
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 12 Sep 2023 Status changed from active, no longer recruiting to completed.
- 28 Nov 2022 Planned End Date changed from 1 Sep 2022 to 1 Sep 2023.
- 11 Oct 2021 Planned End Date changed from 15 Sep 2022 to 1 Sep 2022.